{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:02Z","timestamp":1791327422271,"version":"4.3.1"},"reference-count":44,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"unspecified","delay-in-days":136,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Blood Synergy grant (#1189490)"],"award-info":[{"award-number":["Blood Synergy grant (#1189490)"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S026646232400028X_sec1\">\n\t    <jats:title>Objectives<\/jats:title>\n\t    <jats:p>Patients with hematological malignancies are likely to develop hypogammaglobulinemia. Immunoglobulin (Ig) is commonly given to prevent infections, but its overall costs and cost-effectiveness are unknown.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S026646232400028X_sec2\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>A systematic review was conducted following the PRISMA guidelines to assess the evidence on the costs and cost-effectiveness of Ig, administered intravenously (IVIg) or subcutaneously (SCIg), in adults with hematological malignancies.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S026646232400028X_sec3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>Six studies met the inclusion criteria, and only two economic evaluations were identified; one cost-utility analysis (CUA) of IVIg versus no Ig, and another comparing IVIg with SCIg. The quality of the evidence was low. Compared to no treatment, Ig reduced hospitalization rates. One study reported no significant change in hospitalizations following a program to reduce IVIg use, and an observational study comparing IVIg with SCIg suggested that there were more hospitalizations with SCIg but lower overall costs per patient. The CUA comparing IVIg versus no Ig suggested that IVIg treatment was not cost-effective, and the other CUA comparing IVIg to SCIg found that home-based SCIg was more cost-effective than IVIg, but both studies had serious limitations.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S026646232400028X_sec4\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>Our review highlighted key gaps in the literature: the cost-effectiveness of Ig in patients with hematological malignancies is very uncertain. Despite increasing Ig use worldwide, there are limited data regarding the total direct and indirect costs of treatment, and the optimal use of Ig and downstream implications for healthcare resource use and costs remain unclear. Given the paucity of evidence on the costs and cost-effectiveness of Ig treatment in this population, further health economic research is warranted.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s026646232400028x","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:51:06Z","timestamp":1715842266000},"source":"Crossref","is-referenced-by-count":7,"title":["A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies"],"prefix":"10.1017","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-5392","authenticated-orcid":false,"given":"Sara","family":"Carrillo de Albornoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Li","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa M.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"S026646232400028X_r40","unstructured":"40. UK Department of Health. Clinical guidelines for immunoglobulin use, Department of Health and Social Care, update to 2nd ed. 2011. Available from: https:\/\/www.gov.uk\/government\/publications\/clinical-guidelines-for-immunoglobulin-use-second-edition-update"},{"key":"S026646232400028X_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108419"},{"key":"S026646232400028X_r32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0094-3"},{"key":"S026646232400028X_r34","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-23"},{"key":"S026646232400028X_r23","unstructured":"23. NICE Developing NICE Guidelines: the manual. Appendix H: Appraisal Checklists, Evidence Tables, GRADE and Economic Profiles. National Institute for Health and Care Excellence (NICE); 2022."},{"key":"S026646232400028X_r4","first-page":"Cd006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"8","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"S026646232400028X_r39","unstructured":"39. European Medicines Agency Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). European Medicines Agency; 2018."},{"key":"S026646232400028X_r36","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0288-z"},{"key":"S026646232400028X_r10","unstructured":"10. Immunodeficiency UK Update on immunoglobulin supply situation. 2021 [09\/02\/23]; Available from: http:\/\/www.immunodeficiencyuk.org\/whatarepids\/treatment\/immunoglobulinreplacementtherapy\/igavailabiity."},{"key":"S026646232400028X_r43","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14082"},{"key":"S026646232400028X_r5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008073"},{"key":"S026646232400028X_r30","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. a randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","journal-title":"N Engl J Med"},{"key":"S026646232400028X_r16","doi-asserted-by":"publisher","DOI":"10.1159\/000320232"},{"key":"S026646232400028X_r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"S026646232400028X_r35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2012.01201.x"},{"key":"S026646232400028X_r3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00317"},{"key":"S026646232400028X_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.10.004"},{"key":"S026646232400028X_r25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01874.x"},{"key":"S026646232400028X_r33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101261"},{"key":"S026646232400028X_r13","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444700"},{"key":"S026646232400028X_r41","unstructured":"41. BloodStar Criteria for Clinical Use of Immunoglobulin in Australia: Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT). 2020 [07\/04\/22]. Available from: https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621."},{"key":"S026646232400028X_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2020.12.005"},{"key":"S026646232400028X_r12","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.893770"},{"key":"S026646232400028X_r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100596"},{"key":"S026646232400028X_r42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13580"},{"key":"S026646232400028X_r1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033"},{"key":"S026646232400028X_r24","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00312"},{"key":"S026646232400028X_r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2021.01.001"},{"key":"S026646232400028X_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.09.003"},{"key":"S026646232400028X_r15","unstructured":"15. National Blood Authority. National Blood Authority National Report on the Issue and Use of Immunoglobulin (Ig) Annual Report 2017\u201318. National Blood Authority; 2018."},{"key":"S026646232400028X_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.01.002"},{"key":"S026646232400028X_r44","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13223"},{"key":"S026646232400028X_r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"S026646232400028X_r8","unstructured":"8. EBA Supply Project Kick Off. European Blood Alliance. 2022 [09\/02\/23]. Available from: https:\/\/supply-project.eu\/supply-project-kick-off\/."},{"key":"S026646232400028X_r22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"S026646232400028X_r31","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9720-1"},{"key":"S026646232400028X_r6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1807328"},{"key":"S026646232400028X_r38","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2063833"},{"key":"S026646232400028X_r14","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15694"},{"key":"S026646232400028X_r28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107113250202"},{"key":"S026646232400028X_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.11.014"},{"key":"S026646232400028X_r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"S026646232400028X_r29","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12760"},{"key":"S026646232400028X_r7","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000696"}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S026646232400028X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:39:18Z","timestamp":1716806358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S026646232400028X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S026646232400028X"],"URL":"https:\/\/doi.org\/10.1017\/s026646232400028x","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e32"}}